NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.
The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.
The technology, based on the Luminex 100 microbead system, requires less than one hour for users to haplotype samples that involve two-SNP or multi-SNP haplotpyes.
The company adapted the technology for the Luminex platform in a previous Phase 1 SBIR grant. HapScan can also be automated, according to PolyGenyx, using standard liquid handling robots. The company is developing software for the automation of haplotype scoring.